With so much breaking news surrounding SGLT-2 Inhibitors at ADA, what conclusions can we draw? Viewpoints from our guest editorialist David Kliff, and DIC advisory board member Dr. George Bakris.

At the 2016 conference in New Orleans, the latest research on SGLT-2 Inhibitors was on display.

The National Institute of Health and Care Excellence (NICE) has recommended that SGLT-2 inhibitors on the UK market can be used earlier in patients with diabetes

Male, 32 years of age. Works erratic hours. Recently came up with a plan of how to remember to take his meds. He started setting up and taking his pill box with him. He has succeeded at taking his medications and taking them on time…all except his injectable medications.

Do you prefer to watch our video interviews with recognized diabetes doctors and experts, or read transcriptions of the interviews? 1) Videos 2) Transcripts 3) Both Please let us know -- follow the link to respond!

Elevated 1-hour level proves significant despite 2-hour level within normal glucose tolerance range.

Exercise shown to have some AFib-specific benefits.

Harvard researchers find as many as 40 percent of cancer cases, and half of cancer deaths, come down to things people could easily change.

Senseonics' Eversense™ 90-day implantable CGM approved in Europe.

Study suggests wine consumption offers greater protection against type 2 risk, compared with beer or other alcoholic beverages.